LDS/Medical Tests/GBA, Gaucher Disease Mutation Analysis

GBA, Gaucher Disease Mutation Analysis

Gaucher disease (GD) is an autosomally inherited disorder in which a metabolic deficiency of the enzyme glucocerebrosidase occurs resulting in the accumulation of lipids throughout the body, especially in the bone marrow, liver, and spleen. Although manifestations of disease vary, the most common symptoms of Gaucher disease are an abnormally enlarged liver and/or spleen, anemia, thrombocytopenia, and skeletal abnormalities.

There are three major GD clinical types (1, 2, and 3) and two subtypes: perinatal-lethal and cardiovascular. GD type 1 is characterized by evidence of bone disease, hepatosplenomegaly, anemia, thrombocytopenia, and lung disease. GD types 2 and 3 are characterized by the presence of neurologic disease and are distinguished by age of onset and progression of disease. Type 2 GD shows onset before the age of two, limited psychomotor development, and rapid disease progression with death by age 2-4 years. Type 3 GD may have onset before the age of 2 years but has a slower progression than Type 2 resulting in potentially longer life expectancy. The perinatal-lethal subtype has primary central nervous symptom pyramidal signs with no bone disease but has ichthyosiform or collodion skin changes. The cardiovascular subtype has oculomotor apraxia of the central nervous system with bone disease, and mild splenomegaly, and calcification of mitral and aortic valves.

Targeted mutation analysis involves the GBA gene where mutations are known to cause GD. The four common mutations are N3750S, L444P, 84GG, and IVS2+1.

  • In the Ashkenazi Jewish population, four mutations in the GBA gene account for approximately 90% of disease causing alleles
  • In the non-Jewish population, four mutations in the GBA gene account for approximately 50-60% of disease causing alleles

Sequence analysis of the GBA coding region is used to detect mutations.

  • Prenatal diagnosis of Gaucher Disease
  • Carrier testing for at-risk individuals
  • Confirm diagnosis in proband

Increased (Positive) in:

  • Gaucher Disease

Negative for Mutation Analyzed
 
 

 

Targeted mutation analysis by Sanger sequencing or next generation sequencing. 

Whole Blood ACD (Yellow) or EDTA (Lavender).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Acid β-glucosylceramidase enzyme activity assay, Bone Marrow biopsy examination, Ashkenazi Jewish Diseases Panel, Mucolipidosis, Type IV (MCOLN1) 2 Mutations, Niemann-Pick, Type A (SMPD1) 4 Mutations, Tay-Sachs (HEXA) 7 Mutations.

1-2 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login